[12] Patent
[11] Patent No.:GC0013757  
[45] Date of Publishing the Grant of the Patent: 9/Sep /2025                102/2025  		 Number of the Decision to Grant the Patent:2025/203283
Date of the Decision to Grant the Patent:03/Aug/2025

[21] Application No.:GC 2014-26346

[22] Filing Date:30/1/2014

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
US
US
US
US
31/1/2013
4/3/2013
30/5/2013
27/8/2013
30/10/2013
21/11/2013
 61/759,320
61/772,292
61/828,899
61/870,729
61/897,793
61/907,332

[72] Inventors:1- Ben CHAL،2- Erik MOGALIAN،3- Rowchanak PAKDAMAN،4- Reza OLIYAI،5- Dimitrios STEFANIDIS،6- Vahid ZIA

[73] Owner: GILEAD PHARMASSET LLC, 333 Lakeside Drive, Foster City, USA

[74] Agent: Abu-Gazaleh Intellectual Property L.L.C

  

 

   

[51]IPC:
Int. Cl.: A61K 31/501, 31/513, 9/16, 9/20 (2006.01)

[56] Cited Documents:

-WO 2011156757 A1 (William E. Delaney, Iv William A. Lee David W. Oldach Franck Rousseau) 15 December 2011  
Examiner: PH. Sarah A. AlGrainies

[54] COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
[57] Abstract: Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.
No. of claims: 16     No. of figures: 11


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.